Comparative Pharmacology
Head-to-head clinical analysis: CHRONULAC versus GLYCOPREP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHRONULAC versus GLYCOPREP.
CHRONULAC vs GLYCOPREP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. It is hydrolyzed by colonic bacteria to form low molecular weight acids (mainly lactic and acetic acid), which osmotically draw water into the colon, softening stools and increasing stool frequency. Additionally, lactulose decreases colonic pH, which traps ammonia (NH3) as ammonium (NH4+), reducing serum ammonia levels.
Glycopyrrolate is a competitive antagonist of acetylcholine at muscarinic receptors, thereby inhibiting the effects of parasympathetic nervous system activation. It does not cross the blood-brain barrier significantly, producing peripheral anticholinergic effects.
10-30 mL orally once daily to twice daily; for acute constipation, 20-30 mL initially; for hepatic encephalopathy, 30-60 mL every 1-2 hours to achieve 2-3 soft stools daily.
Adults: 10 units subcutaneously 30 minutes before first meal of the day, then 5 units after each subsequent meal. Total daily dose should not exceed 30 units.
None Documented
None Documented
Terminal elimination half-life approximately 1.5-2.5 hours in adults with normal renal function; may be prolonged to 4-8 hours in patients with renal impairment.
Terminal half-life 1.5-2 hours in adults; prolonged in renal impairment (up to 10-12 hours in anuria).
Primarily renal (as unchanged drug and metabolites): ~40-50% of dose excreted in urine within 24 hours; biliary/fecal elimination accounts for the remainder, with approximately 2-5% recovered in feces as parent compound.
Primarily renal (90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <10%.
Category C
Category C
Osmotic Laxative
Osmotic Laxative